Company intelligence / Profile preview
Fusix Biotech GmbH
Munich, Bavaria, Germanyfusixbiotech.de ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Fusix Biotech has demonstrated efficacy and safety in preclinical models for its InFUSE platform. The company has achieved several scientific milestones, secured €1.6M in funding, and initiated scalable manufacturing process development. No clinical trial results are yet available as of early 2025
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic viruses (synthetic/fusogenic oncolytic vector-based platform)gene therapy vectors encoding therapeutic genes
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Strategic partnerships sought with industry leaders in biotech/pharma/healthcare to accelerate clinical/commercial development; specific partners not named as of May 2025
Beyond the preview
Go deeper on Fusix Biotech GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fusix Biotech GmbH.